Bloom to Expand into Europe with New Garden Pharma Partnership

*LONDON —* The Bloom Brand, a U.S. leader in cannabis vape, plans to make
its international debut in the United Kingdom through an exclusive
partnership with New Garden Pharma, a leading European EU-GMP cannabis
operator. Together, the two companies will launch Bloom’s award-winning
Classic and Live vape collections in the UK in Q1 2026.

This marks Bloom’s first international market expansion, as the company
continues its global growth strategy with additional EU markets in
development for 2026 and beyond. UK patients will gain access to Bloom’s
superior formulations and proprietary hardware systems.

For more than a decade, Bloom has built its reputation on delivering
terpene-rich, flavor-forward strains paired with reliable technology. The
brand has an established and leading presence across leading U.S. markets
including California, Illinois, Florida, Michigan, Missouri, New Jersey,
New Mexico, New York, and Virginia.

“Expanding into the UK is a pivotal step towards our mission to reshape the
global cannabis experience,” said Ovidiu (David) Chiorpec, Director of
Business Development at Bloom. “We’ve spent over a decade building a brand
that patients trust in the U.S., and we’re excited to introduce the UK
consumer to a new level of excellence and sophistication in the vape
category.”

New Garden Pharma, medical subsidiary of New Garden Group, is a trusted
name in European cannabis manufacturing who combines a unique supply chain
model with a proven track record in regulatory compliance and market
expansion. With established infrastructure across the continent, the
company will lead Bloom’s UK entry — ensuring a compliant, efficient, and
scalable launch across all channels.

“We’re excited to welcome Bloom to the UK market,” said Alexey Brylev, CEO
of New Garden Group. “As an established operator across European medical
cannabis markets, we bring the EU-GMP manufacturing expertise, local
insight, and regulatory know-how needed to help global brands thrive. This
partnership reflects our broader mission: to deliver world-class products
to European patients and to raise the bar for quality, safety, and
innovation across the continent.”